
Sign up to save your podcasts
Or


Today, 20 years after we sequenced the first human genome, we’re starting to see the fruits of genomics. Instead of treating symptoms, researchers are focused on finding cures for once chronic and fatal diseases. We’re starting to reimagine medicine in ways previously thought impossible. This week on the For Your Innovation Podcast, we’re joined by Dr. Samarth Kulkarni, Chief Executive Officer of CRISPR Therapeutics. Sam joined CRISPR in early 2015 as Chief Business Officer. Two years later, in 2017, he was appointed to CEO. In addition to his expertise in biotech strategy and operations, Sam has spearheaded initiatives in personalized medicine, immunotherapy, and other therapeutic technologies. In today’s episode, we’re also joined by ARK’s CEO/ CIO, Cathie Wood, who helps provides her insights on macrotrends currently affecting the biotech industry as we come out of last week’s J.P. Morgan Health Care conference. Tune in to hear more on costs of genomic therapies, AI integration, and why Sam believes the “roaring twenties” of biotech may be on the horizon.
By ARK Invest4.7
388388 ratings
Today, 20 years after we sequenced the first human genome, we’re starting to see the fruits of genomics. Instead of treating symptoms, researchers are focused on finding cures for once chronic and fatal diseases. We’re starting to reimagine medicine in ways previously thought impossible. This week on the For Your Innovation Podcast, we’re joined by Dr. Samarth Kulkarni, Chief Executive Officer of CRISPR Therapeutics. Sam joined CRISPR in early 2015 as Chief Business Officer. Two years later, in 2017, he was appointed to CEO. In addition to his expertise in biotech strategy and operations, Sam has spearheaded initiatives in personalized medicine, immunotherapy, and other therapeutic technologies. In today’s episode, we’re also joined by ARK’s CEO/ CIO, Cathie Wood, who helps provides her insights on macrotrends currently affecting the biotech industry as we come out of last week’s J.P. Morgan Health Care conference. Tune in to hear more on costs of genomic therapies, AI integration, and why Sam believes the “roaring twenties” of biotech may be on the horizon.

3,372 Listeners

1,286 Listeners

533 Listeners

2,176 Listeners

1,092 Listeners

940 Listeners

1,213 Listeners

614 Listeners

908 Listeners

559 Listeners

9,927 Listeners

449 Listeners

131 Listeners

466 Listeners

36 Listeners